TL;DR
This study provides real-world evidence supporting the use of intravenous thrombolysis (rt-PA) for acute ischemic stroke (AIS) patients within the 3-4.5 hour window after symptom onset. The findings indicate that this extended treatment window is associated with improved functional recovery without increasing risks of symptomatic intracerebral hemorrhage, early neurological deterioration, or mortality.
What Problem Does This Paper Address?
Acute ischemic stroke (AIS) is a major cause of death and disability. Prompt treatment with intravenous recombinant tissue plasminogen activator (rt-PA) is crucial for restoring blood flow and improving outcomes. While rt-PA is approved for AIS within 3 hours of symptom onset, its use in the extended 3-4.5 hour window has not been universally approved by regulatory bodies like the FDA, despite evidence from clinical trials suggesting its efficacy and safety. This creates a gap between clinical trial findings and real-world application, particularly in Asian populations. This study aims to bridge that gap by investigating the effectiveness and safety of rt-PA in AIS patients treated within the 3-4.5 hour window using data from a large, multicenter registry in Taiwan.
Methods
The researchers conducted a retrospective, matched cohort study using data from the Taiwan Stroke Registry (TSR), a multicenter registry collecting information on stroke patients. They identified two groups:
- Treatment Group: Patients who received rt-PA for AIS between 3 and 4.5 hours after symptom onset.
- Control Group: Age- and sex-matched patients who did not receive rt-PA, excluding those with contraindications.
The primary outcome measured was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0-1 (indicating minimal or no disability) at 90 days post-stroke. Secondary outcomes included mRS scores of 0-2, early neurological deterioration, and 3-month mortality. Safety outcomes focused on any intracerebral hemorrhage (ICH) and symptomatic ICH. The study also included a subgroup analysis comparing standard-dose (0.9 mg/Kg) and low-dose (0.6 mg/Kg) rt-PA administration.
Datasets
The study utilized data from the Taiwan Stroke Registry (TSR), a multicenter registry that prospectively collected information from 16 participating hospitals between 2008 and 2017. This registry contains data on patient demographics, medical history, laboratory results, stroke treatments, and clinical outcomes.
Key Insights and Ideas
- Bridging the Evidence Gap: The study provides crucial real-world data from an Asian population, supporting the use of rt-PA in the 3-4.5 hour window, which is particularly important given the lack of FDA approval for this indication.
- Improved Functional Recovery: The extended window treatment demonstrably leads to better functional outcomes, suggesting that more patients can benefit from timely intervention.
- Safety Profile Maintained: Importantly, the study found no significant increase in symptomatic ICH, early neurological deterioration, or mortality in the rt-PA treated group compared to the control group, reinforcing the safety of this extended treatment.
- Dose Equivalence: The analysis of standard versus low-dose rt-PA suggests that both regimens are similarly effective and safe for patients treated within the 3-4.5 hour window, offering flexibility in clinical practice.
- Independent Predictors of Good Outcome: The study identified key factors associated with favorable outcomes, including younger age, lower NIHSS scores, rt-PA use, and absence of ICH, highlighting areas for targeted intervention and risk stratification.
Key Results
- Primary Outcome: 34.0% of patients in the rt-PA treatment group achieved an mRS score of 0-1 at 90 days, compared to 22.7% in the control group. This represents a significant improvement with an odds ratio of 1.75 (95% CI, 1.27-2.42; P=0.001).
- Secondary Outcomes: The treatment group also showed a significantly higher proportion of patients with mRS scores of 0-2 (47.9% vs. 40.1%; OR, 1.37; P=0.033). There were no significant differences in early neurological deterioration or 3-month mortality rates between the groups.
- Safety: While the overall incidence of any ICH was higher in the treatment group (17.4% vs. 8.6%; OR, 2.25; P<0.001), the rates of symptomatic ICH were not significantly different between the groups across various definitions.
- Dose Subgroup: No significant differences in effectiveness or safety outcomes were observed between patients receiving standard-dose and low-dose rt-PA.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: The study's retrospective nature means that data was collected from existing databases, which may lead to missing information and potential biases.
- Short Follow-up Period: The data was collected over a relatively short follow-up period after stroke onset.
- Non-Randomized and Non-Matched: While a matched cohort was used, the study was not randomized, and potential imbalances in patient characteristics might have influenced the results.
- Investigator Discretion: The decision to administer rt-PA was at the discretion of individual investigators, which could introduce variability.
Future work could involve prospective, randomized controlled trials to further validate these findings and explore optimal treatment strategies within this extended time window. The authors also suggest that the findings support the broader adoption of rt-PA for AIS patients within the 3-4.5 hour window, even without explicit FDA approval, under careful clinical observation.
Summary updated